Unique copper-induced oligomers mediate alpha-synuclein toxicity

FASEB Journal

Volumn 23, Issue 8, 2009, Pages 2384-2393

  Wright, Josephine A ^a   Wang, Xiaoyan ^a   Brown, David R ^a  

^a University of Bath   (United Kingdom)

Author keywords

Cell death; Lewy bodies; Metal; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; COPPER; IRON; OLIGOMER; RECOMBINANT PROTEIN;

ARTICLE; CELL CULTURE; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IN VIVO STUDY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; STELLATE CELL; CELL LINE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; GENETICS; IN VITRO STUDY; LEWY BODY; PARKINSON DISEASE; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; CELL DEATH; CELL LINE; COPPER; HUMANS; LEWY BODIES; MICROSCOPY, ELECTRON, TRANSMISSION; NERVE DEGENERATION; PARKINSON DISEASE; POINT MUTATION; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS;

EID: 68849102707     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-130039     Document Type: Article

References (84)

1. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95, 6469-6473 (Pubitemid 28249037)
2. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840
3. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32 (Pubitemid 24154659)
4. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., and Saitoh, T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90, 11282-11286 (Pubitemid 23354413)
5. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., and Bjorklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791 (Pubitemid 37465827)
6. Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., and Price, D. L. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99, 8968-8973 (Pubitemid 34693667)
7. Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N., and Aebischer, P. (2002) α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 99, 10813-10818 (Pubitemid 34907059)
8. Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., and Lee, M. K. (2006) Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50 (Pubitemid 43089519)
9. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (Pubitemid 30112148)
10. Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y., and Mochizuki, H. (2006) Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 341, 1088-1095 (Pubitemid 43221777)
11. Duda, J. E., Lee, V. M., and Trojanowski, J. Q. (2000) Neuropathology of synuclein aggregates. J. Neurosci. Res. 61, 121-127
12. El-Agnaf, O. M., and Irvine, G. B. (2000) Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130, 300-309
13. Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., and Kostka, M. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220-9232 (Pubitemid 47312071)
14. Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., and McLean, P. J. (2008) Formation of toxic oligomeric α-synuclein species in living cells. PLoS ONE 3, e1867 (Pubitemid 351954367)
15. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., and Lansbury, P. T., Jr. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819
16. Albani, D., Peverelli, E., Rametta, R., Batelli, S., Veschini, L., Negro, A., and Forloni, G. (2004) Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J. 18, 1713-1715 (Pubitemid 39561660)
17. Bodles, A. M., Guthrie, D. J., Harriott, P., Campbell, P., and Irvine, G. B. (2000) Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem. 267, 2186-2194 (Pubitemid 30220063)
18. Du, H. N., Tang, L., Luo, X. Y., Li, H. T., Hu, J., Zhou, J. W., and Hu, H. Y. (2003) A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human α-synuclein. Biochemistry 42, 8870-8878 (Pubitemid 36899831)
19. El-Agnaf, O. M., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., and Wallace, A. (1998) Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett. 440, 71-75 (Pubitemid 28558738)
20. Forloni, G., Bertani, I., Calella, A. M., Thaler, F., and Invernizzi, R. (2000) Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann. Neurol. 47, 632-640 (Pubitemid 30261899)
21. Lee, E. N., Cho, H. J., Lee, C. H., Lee, D., Chung, K. C., and Paik, S. R. (2004) Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry 43, 3704-3715 (Pubitemid 38391725)
22. Seo, J. H., Rah, J. C., Choi, S. H., Shin, J. K., Min, K., Kim, H. S., Park, C. H., Kim, S., Kim, E. M., Lee, S. H., Lee, S., Suh, S. W., and Suh, Y. H. (2002) Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16, 1826-1828
23. Sung, J. Y., Kim, J., Paik, S. R., Park, J. H., Ahn, Y. S., and Chung, K. C. (2001) Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J. Biol. Chem. 276, 27441-27448 (Pubitemid 37410661)
24. El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., and Allsop, D. (2006) Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419-425
25. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., and Markesbery, W. R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52
26. Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., and Marsden, C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836 (Pubitemid 19140770)
27. Pall, H. S., Williams, A. C., Blake, D. R., Lunec, J., Gutteridge, J. M., Hall, M., and Taylor, A. (1987) Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 2, 238-241
28. Binolfi, A., Rasia, R. M., Bertoncini, C. W., Ceolin, M., Zweckstetter, M., Griesinger, C., Jovin, T. M., and Fernandez, C. O. (2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity, and fibrillation enhancement. J. Am. Chem. Soc. 128, 9893-9901 (Pubitemid 44147975)
29. Golts, N., Snyder, H., Frasier, M., Theisler, C., Choi, P., and Wolozin, B. (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277, 16116-16123 (Pubitemid 34967897)
30. 2. J. Neurochem. 84, 1128-1142
31. Rasia, R. M., Bertoncini, C. W., Marsh, D., Hoyer, W., Cherny, D., Zweckstetter, M., Griesinger, C., Jovin, T. M., and Fernandez, C. O. (2005) Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 102, 4294-4299 (Pubitemid 40397105)
32. Uversky, V. N., Li, J., and Fink, A. L. (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284-44296 (Pubitemid 37384003)
33. Drayer, B., Burger, P., Darwin, R., Riederer, S., Herfkens, R., and Johnson, G. A. (1986) MRI of brain iron. AJR. Am. J. Roentgenol. 147, 103-110
34. Goldberg, W. J., and Allen, N. (1981) Determination of Cu, Mn, Fe, and Ca in six regions of normal human brain, by atomic absorption spectroscopy. Clin. Chem. 27, 562-564
35. Warren, P. J., Earl, C. J., and Thompson, R. H. (1960) The distribution of copper in human brain. Brain 83, 709-717
36. Zhang, L., Zhang, C., Zhu, Y., Cai, Q., Chan, P., Ueda, K., Yu, S., and Yang, H. (2008) Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res. 1244, 40-52
37. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108
38. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (Pubitemid 27443610)
39. Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (Pubitemid 38166992)
40. Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., and Tabaton, M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65-67 (Pubitemid 30332379)
41. Lee, P. H., Lee, G., Park, H. J., Bang, O. Y., Joo, I. S., and Huh, K. (2006) The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J. Neural Transm. 113, 1435-1439 (Pubitemid 44435881)
42. Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., and El-Agnaf, O. M. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166 (Pubitemid 44331776)
43. Squitti, R., Barbati, G., Rossi, L., Ventriglia, M., Dal Forno, G., Cesaretti, S., Moffa, F., Caridi, I., Cassetta, E., Pasqualetti, P., Calabrese, L., Lupoi, D., and Rossini, P. M. (2006) Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau. Neurology 67, 76-82 (Pubitemid 44305465)
44. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., Louis, J. C., Wypych, J., Biere, A. L., and Citron, M. (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843-9846 (Pubitemid 129517964)
45. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C., Citron, M., and Biere, A. L. (1999) α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512 (Pubitemid 129519387)
46. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 97, 571-576
47. Ding, T. T., Lee, S. J., Rochet, J. C., and Lansbury, P. T., Jr. (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209-10217
48. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291
49. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., and Lansbury, P. T., Jr. (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102
50. Biere, A. L., Wood, S. J., Wypych, J., Steavenson, S., Jiang, Y., Anafi, D., Jacobsen, F. W., Jarosinski, M. A., Wu, G. M., Louis, J. C., Martin, F., Narhi, L. O., and Citron, M. (2000) Parkinson's disease-associated α-synuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 275, 34574-34579 (Pubitemid 30819233)
51. Giasson, B. I., Murray, I. V., Trojanowski, J. Q., and Lee, V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386 (Pubitemid 37376605)
52. Ohtake, H., Limprasert, P., Fan, Y., Onodera, O., Kakita, A., Takahashi, H., Bonner, L. T., Tsuang, D. W., Murray, I. V., Lee, V. M., Trojanowski, J. Q., Ishikawa, A., Idezuka, J., Murata, M., Toda, T., Bird, T. D., Leverenz, J. B., Tsuji, S., and La Spada, A. R. (2004) Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63, 805-811 (Pubitemid 39297638)
53. Binolfi, A., Lamberto, G. R., Duran, R., Quintanar, L., Bertoncini, C. W., Souza, J. M., Cervenansky, C., Zweckstetter, M., Griesinger, C., and Fernandez, C. O. (2008) Site-specific interactions of Cu(II) with α and β-synuclein: bridging the molecular gap between metal binding and aggregation. J. Am. Chem. Soc. 130, 11801-11812
54. Yamin, G., Munishkina, L. A., Karymov, M. A., Lyubchenko, Y. L., Uversky, V. N., and Fink, A. L. (2005) Forcing nonamyloidogenic β-synuclein to fibrillate. Biochemistry 44, 9096-9107
55. Fredenburg, R. A., Rospigliosi, C., Meray, R. K., Kessler, J. C., Lashuel, H. A., Eliezer, D., and Lansbury, P. T., Jr. (2007) The impact of the E46K mutation on the properties of α-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107-7118
56. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-11613 (Pubitemid 32911305)
57. Bharathi, and Rao, K. S. (2007) Thermodynamics imprinting reveals differential binding of metals to α-synuclein: relevance to Parkinson's disease. Biochem. Biophys. Res. Commun. 359, 115-120
58. Giasson, B. I., Uryu, K., Trojanowski, J. Q., and Lee, V. M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622 (Pubitemid 129518144)
59. van Raaij, M. E., Segers-Nolten, I. M., and Subramaniam, V. (2006) Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants. Biophys. J. 91, L96-L98
60. Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin, T. M., and Subramaniam, V. (2002) Dependence of alpha-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322, 383-393
61. Heise, H., Hoyer, W., Becker, S., Andronesi, O. C., Riedel, D., and Baldus, M. (2005) Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc. Natl. Acad. Sci. U. S. A. 102, 15871-15876 (Pubitemid 41552835)
62. Dusa, A., Kaylor, J., Edridge, S., Bodner, N., Hong, D. P., and Fink, A. L. (2006) Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry 45, 2752-2760 (Pubitemid 43297333)
63. McLean, P. J., Kawamata, H., Ribich, S., and Hyman, B. T. (2000) Membrane association and protein conformation of α-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275, 8812-8816 (Pubitemid 30180236)
64. Fortin, D. L., Nemani, V. M., Voglmaier, S. M., Anthony, M. D., Ryan, T. A., and Edwards, R. H. (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 25, 10913-10921 (Pubitemid 41692621)
65. Volles, M. J., and Lansbury, P. T., Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602
66. Furukawa, K., Matsuzaki-Kobayashi, M., Hasegawa, T., Kikuchi, A., Sugeno, N., Itoyama, Y., Wang, Y., Yao, P. J., Bushlin, I., and Takeda, A. (2006) Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J. Neurochem. 97, 1071-1077
67. Bhatia, R., Lin, H., and Lal, R. (2000) Fresh and globular amyloid β protein (1-42) induces rapid cellular degeneration: evidence for AβP channel-mediated cellular toxicity. FASEB J. 14, 1233-1243 (Pubitemid 30350405)
68. Kawahara, M., Kuroda, Y., Arispe, N., and Rojas, E. (2000) Alzheimer's β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J. Biol. Chem. 275, 14077-14083 (Pubitemid 30339682)
69. Zhu, Y. J., Lin, H., and Lal, R. (2000) Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AβP-channel-mediated cellular toxicity. FASEB J. 14, 1244-1254 (Pubitemid 30350406)
70. Clayton, D. F., and George, J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249-254
71. Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., Lu, B., and Nussbaum, R. L. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22, 8797-8807 (Pubitemid 35379049)
72. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., and Lee, V. M. (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220
73. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinsky, N., Verdugo, J. M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., and Rosenthal, A. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252 (Pubitemid 30316525)
74. Eliezer, D., Kutluay, E., Bussell, R., Jr., and Browne, G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 1061-1073 (Pubitemid 33029953)
75. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M., and Sudhof, T. C. (2005) Alpha-synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123, 383-396 (Pubitemid 41546670)
76. Souza, J. M., Giasson, B. I., Lee, V. M., and Ischiropoulos, H. (2000) Chaperone-like activity of synucleins. FEBS Lett. 474, 116-119
77. El-Agnaf, O. M., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., Curran, M. D., Court, J. A., Mann, D. M., Ikeda, S., Cookson, M. R., Hardy, J., and Allsop, D. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945-1947
78. Lee, H. J., Patel, S., and Lee, S. J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016-6024 (Pubitemid 40911433)
79. Sung, J. Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., Oh, Y. J., Lee, S. T., Paik, S. R., and Chung, K. C. (2005) Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 25216-25224 (Pubitemid 40934615)
80. Lee, S. J. (2008) Origins and effects of extracellular α-synuclein: implications in Parkinson's disease. J. Mol. Neurosci. 34, 17-22
81. Lee, H. J., Suk, J. E., Bae, E. J., Lee, J. H., Paik, S. R., and Lee, S. J. (2008) Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int. J. Biochem. Cell Biol. 40, 1835-1849
82. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., Laughton, K., Li, Q. X., Charman, S. A., Nicolazzo, J. A., Wilkins, S., Deleva, K., Lynch, T., Kok, G., Ritchie, C. W., Tanzi, R. E., Cappai, R., Masters, C. L., Barnham, K. J., and Bush, A. I. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55 (Pubitemid 351905863)
83. Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., Wilson, J., and Ritchie, C. W. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779-786
84. Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q. X., Tammer, A., Carrington, D., Mavros, C., Volitakis, I., Xilinas, M., Ames, D., Davis, S., Beyreuther, K., Tanzi, R. E., and Masters, C. L. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691 (Pubitemid 37521621)